医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
1期
268-269
,共2页
来士普%慢性头痛%睡眠质量%疗效
來士普%慢性頭痛%睡眠質量%療效
래사보%만성두통%수면질량%료효
lexapro%chronicc headache%sleep quality%efficacy
目的：探讨来士普治疗慢性头痛的临床疗效。方法：2012年10月至2013年10月期间，我院诊治的48例慢性头痛患者，均接受来士普治疗，根据视觉模拟量表（visual analogue scale, VAS）和匹兹堡睡眠质量指数（Pittsburgh sleep quality index, PSQI），对治疗前后头痛程度、睡眠质量、不良反应，进行观察和比较。结果：与治疗前相比，治疗后VAS评分和PSQI评分均明显降低，头痛程度和睡眠质量均得到了明显改善，P<0.05，并且治疗期间没有出现严重不良反应。结论：对于慢性头痛患者，来士普治疗具有较高临床疗效和治疗安全性，明显改善患者睡眠质量，值得临床推广。
目的：探討來士普治療慢性頭痛的臨床療效。方法：2012年10月至2013年10月期間，我院診治的48例慢性頭痛患者，均接受來士普治療，根據視覺模擬量錶（visual analogue scale, VAS）和匹玆堡睡眠質量指數（Pittsburgh sleep quality index, PSQI），對治療前後頭痛程度、睡眠質量、不良反應，進行觀察和比較。結果：與治療前相比，治療後VAS評分和PSQI評分均明顯降低，頭痛程度和睡眠質量均得到瞭明顯改善，P<0.05，併且治療期間沒有齣現嚴重不良反應。結論：對于慢性頭痛患者，來士普治療具有較高臨床療效和治療安全性，明顯改善患者睡眠質量，值得臨床推廣。
목적：탐토래사보치료만성두통적림상료효。방법：2012년10월지2013년10월기간，아원진치적48례만성두통환자，균접수래사보치료，근거시각모의량표（visual analogue scale, VAS）화필자보수면질량지수（Pittsburgh sleep quality index, PSQI），대치료전후두통정도、수면질량、불량반응，진행관찰화비교。결과：여치료전상비，치료후VAS평분화PSQI평분균명현강저，두통정도화수면질량균득도료명현개선，P<0.05，병차치료기간몰유출현엄중불량반응。결론：대우만성두통환자，래사보치료구유교고림상료효화치료안전성，명현개선환자수면질량，치득림상추엄。
Objective: To study the clinical efficacy of lexapro in the treatment of chronicc headache. Methods: The 48 patients with chronicc headache in our hospital during the period from Oct 2012 to Oct 2013 were treated by lexapro. The VAS scores and PSQI scores between the pre- and post-treatment were observed and compared according to the visual analogue scale (VAS) and Pittsburgh sleep quality index (PSQI). Results: compared with the pre-treatment, the VAS scores and PSQI scores were significantly reduced and the headache level and sleep quality were obviously improved without seious adverse reactions during the treatment period, P<0.05. Conclusion: For the patients with chronicc headache, the treatment of lexapro has the high clinical efficacy and safety, can significantly improve the sleep quality, and is worthy of clinical promotion.
